Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Novocure Ltd Ord Sh (NVCR)

Novocure Ltd Ord Sh (NVCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,311,261
  • Shares Outstanding, K 99,641
  • Annual Sales, $ 351,320 K
  • Annual Income, $ -7,230 K
  • 60-Month Beta 1.97
  • Price/Sales 18.80
  • Price/Cash Flow N/A
  • Price/Book 30.12

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate 0.07
  • Number of Estimates 4
  • High Estimate 0.12
  • Low Estimate 0.04
  • Prior Year -0.13
  • Growth Rate Est. (year over year) +153.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
53.40 +29.40%
on 03/23/20
75.46 -8.43%
on 03/10/20
-0.63 (-0.90%)
since 03/06/20
3-Month
53.40 +29.40%
on 03/23/20
98.84 -30.09%
on 01/22/20
-7.01 (-9.21%)
since 01/06/20
52-Week
41.51 +66.47%
on 04/17/19
98.84 -30.09%
on 01/22/20
+22.76 (+49.12%)
since 04/05/19

Most Recent Stories

More News
Novocure Provides Business Update Related to COVID-19

Novocure (NASDAQ: NVCR) today provided an update on its response to the global COVID-19 pandemic and an initial evaluation of the impact the pandemic may have on Novocure's general business operations...

NVCR : 69.10 (+9.09%)
German Federal Joint Committee Updates Medical Care Directive to include Tumor Treating Fields, establishing National Reimbursement for Optune in Germany

Novocure (NASDAQ: NVCR) today announced that the German Federal Joint Committee, or G-BA, has updated its directive for Contracted Medical Care to include Tumor Treating Fields, establishing national reimbursement...

NVCR : 69.10 (+9.09%)
Novocure Announces Optune Lua(TM) as the Brand Name for the NovoTTF-100L(TM) System

Novocure (NASDAQ: NVCR) announced today that Optune Lua is the brand name for the NovoTTF-100L System in malignant pleural mesothelioma (MPM). The U.S. Food and Drug Administration (FDA) previously approved...

NVCR : 69.10 (+9.09%)
Preclinical Data Show Tumor Treating Fields Induces Immunogenic Cell Death Resulting in Enhanced Antitumor Efficacy When Combined with Anti-PD-1 Therapy

Novocure (NASDAQ: NVCR) announced today that preclinical data on Tumor Treating Fields in combination with anti-PD-1 therapy were published in the peer-reviewed journal, Cancer Immunology, Immunotherapy....

NVCR : 69.10 (+9.09%)
NovoCure (NVCR) Q4 Earnings and Revenues Beat Estimates

NovoCure (NVCR) delivered earnings and revenue surprises of 300.00% and 0.11%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

NVCR : 69.10 (+9.09%)
Novocure Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Company Update

--Second quarter of positive net income with $0.04 in earnings per share

NVCR : 69.10 (+9.09%)
NASDAQ Reaches New Closing High as Rebound Continues

NASDAQ Reaches New Closing High as Rebound Continues

LYV : 34.51 (+2.80%)
NVCR : 69.10 (+9.09%)
VRTX : 255.30 (+7.13%)
GDS : 53.80 (+5.08%)
ETSY : 46.46 (+21.78%)
AYX : 89.90 (+9.98%)
HTHT : 29.28 (+2.49%)
MGM : 12.91 (+22.02%)
NEM : 50.11 (+6.28%)
WYNN : 56.73 (+16.97%)
SIMO : 41.00 (+6.36%)
RXN : 22.21 (+14.84%)
GOOGL : 1,183.19 (+8.28%)
NVDA : 268.40 (+10.04%)
SQQQ : 16.95 (-21.02%)
SPXU : 21.18 (-20.20%)
BRY : 2.26 (+0.89%)
Expand Your Portfolio with this First Profit Stock Screener

Expand Your Portfolio with this First Profit Stock Screener

SPWR : 5.55 (+17.34%)
NVCR : 69.10 (+9.09%)
NEP : 40.18 (+6.10%)
EVER : 27.68 (+14.57%)
CRSP : 42.17 (+7.08%)
Relief Rally Snaps the Dow's 5-Day Losing Skid

Relief Rally Snaps the Dow's 5-Day Losing Skid

CREE : 38.18 (+13.50%)
RLI : 87.71 (+5.55%)
SCS : 9.13 (+11.07%)
SAM : 362.54 (+1.43%)
WYNN : 56.73 (+16.97%)
LNG : 34.17 (+6.12%)
TXN : 108.96 (+8.98%)
WY : 17.10 (+11.47%)
TWTR : 24.93 (+7.97%)
AMZN : 1,997.59 (+4.77%)
BZUN : 28.87 (+10.87%)
GDS : 53.80 (+5.08%)
IRBT : 42.35 (+11.39%)
LYV : 34.51 (+2.80%)
NVCR : 69.10 (+9.09%)
SPR : 19.45 (+5.53%)
CELH : 4.03 (+4.95%)
AMSC : 5.82 (+4.30%)
CLS : 3.49 (+4.49%)
Novocure Announces National Reimbursement in Israel for Optune(R) in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Novocure (NASDAQ: NVCR) announced today that the State of Israel Ministry of Health has added Optune in combination with temozolomide to the Israeli medical services basket for the treatment of patients...

NVCR : 69.10 (+9.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Trade NVCR with:

Business Summary

NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.

See More

Key Turning Points

2nd Resistance Point 72.47
1st Resistance Point 70.78
Last Price 69.10
1st Support Level 66.26
2nd Support Level 63.43

See More

52-Week High 98.84
Fibonacci 61.8% 76.94
Fibonacci 50% 70.18
Last Price 69.10
Fibonacci 38.2% 63.41
52-Week Low 41.51

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar